 SIGA Technologies, Inc. is a commercial-stage pharmaceutical company developing drugs for health security and infectious diseases globally with a market niche in smallpox servicing various government agencies. SIGA Technologies pipeline consists of one core FDA-approved oral drug known as TPOXX tecovirimat, a pipeline of 3 others based on TPOXX-administration-changedsmallpox sub-indications, and one other early-stage smallpox small-molecule formulation. 